March 25, 2015 Kite Pharma to Report Fourth Quarter and Full Year 2014 Financial Results on March 26th, 2015
March 24, 2015 New Data Supporting Arno Therapeutics’ HDAC inhibitor AR-42 Published in The Journal of Urology
March 23, 2015 Capricor Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25, 2015 in New York
March 18, 2015 Capricor Therapeutics Reports Fourth Quarter and Full Year 2014 Financial & Business Highlights
March 17, 2015 Kite Pharma Strengthens Its T Cell Receptor (TCR) Cancer Gene Therapy Platform Through Acquisition of T-Cell Factory B.V. (TCF(TM))
March 12, 2015 Capricor Therapeutics to Hold Fourth Quarter 2014 Business Update Conference Call on March 18, 2015 at 4:30 p.m. EDT
March 5, 2015 Capricor Announces Enrollment of its Phase II Clinical Trial for Cenderitide to Treat Heart Failure
March 2, 2015 Kite Pharma Expands Its Research and Development Collaboration With the National Cancer Institute to Develop a Next Generation of Cancer Immunotherapy Products for Solid Tumors
February 19, 2015 Kite Pharma Establishes Manufacturing Capabilities to Support Development and Commercialization of CAR and TCR Cancer Immunotherapy Products
January 22, 2015 Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy
January 19, 2015 Kite Pharma Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process
January 12, 2015 Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure
January 9, 2015 Kite Pharma Expands Senior Management Team With Appointment of Claudine Prowse, Ph.D., as SVP, Corporate Communications and Investor Relations
January 8, 2015 Kite Pharma Announces Addition of Scott N. Bernstein as Vice President of Intellectual Property Law
January 7, 2015 Kite Pharma Announces Exclusive License With the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat HPV-Associated Cancers
January 6, 2015 Kite Pharma Granted Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy
January 5, 2015 Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies
